The 36-month beta value for CMPS is also noteworthy at 2.25. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CMPS is 84.17M, and at present, short sellers hold a 6.06% of that float. The average trading volume of CMPS on June 04, 2025 was 1.06M shares.
CMPS) stock’s latest price update
Compass Pathways Plc ADR (NASDAQ: CMPS) has experienced a decline in its stock price by -0.63 compared to its previous closing price of 4.59. However, the company has seen a gain of 8.09% in its stock price over the last five trading days. https://www.proactiveinvestors.com reported 2025-06-02 that Meta Platforms Inc (NASDAQ:META, ETR:FB2A, SWX:FB) is planning to let brands fully create and target ads using its artificial intelligence tools by the end of 2025, according to a report in the Wall Street Journal. Citing people familiar with the plans, the report says advertisers will be able to provide a product image and budget, and Meta’s AI will handle everything from generating the content, including text, images and video, to targeting users across Facebook and Instagram. Meta already uses AI to customise ads and suggest variations, but the new tools would go further by offering real-time personalisation based on factors like location. The company is also working on automating budget recommendations. With 3.43 billion global users across its apps, Meta sees advanced AI tools as a way to deliver ad results at scale. The move comes as rivals such as Snap, Pinterest and Reddit ramp up their own AI offerings in an increasingly competitive digital ad market. atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company’s clinical development progress in 2025, highlighting multiple upcoming trial readouts. Proactive: Hello, you’re watching Proactive. Joining me is atai Life Sciences CEO and co-founder Dr Srinivas Rao. Srinivas, very good to speak with you. You’ve had a very busy start to 2025. Let’s start off with the positive topline data of part two of the Beckley Psytech’s Phase 2a trial of BPL-003. It looks pretty encouraging. Dr Srinivas Rao: Yeah. Well, thanks for having me on. Yeah, we’re very excited by that. So this is a continuation of a Phase 2a that we reported the results on last year actually. That was a single administration of BPL-003 in folks who were not taking an SSRI at that time. This is the continuation with those patients that are currently on an SSRI. Once again, we saw very good safety and tolerability and very robust efficacy in this cohort. So certainly important data as we move forward into Phase 3 with this program. The next step here is we’re waiting for the results from the large Phase 2b trial that’s currently ongoing. And if those results are as encouraging as the ones you just mentioned, when would you be expecting to go ahead with the Phase 3 trial? I mean, we haven’t officially guided on that. And of course, the reason for that is it’s going to depend upon the results as well as discussions with the FDA. But generally speaking, we can anticipate something starting sometime next year — obviously, sort of middle of next year, perhaps a little later. So you mentioned data from the Phase 2b study, which is expected in the middle of the year. Srinivas, lots of key readouts are expected this year and going into 2026. Take us through some of the other important ones. Yeah, we’ve got quite a few coming up. So we have the BPL-003 Phase 2b that we were talking about now — that’s mid-year. RL-007, the large Phase 2b in cognitive impairment in schizophrenia, also in the middle of this year. Sort of right on top of this one, we’ll see which one comes first. And then early next year, the VLS-01 Illumina study that’s currently ongoing should be reading out as well. We just recently initiated a Phase 2a study of EMP-01 in social anxiety disorder. That too is expected to read out in the first quarter of next year. And you announced the dosing of the first patients in that EMP-01 trial. Srinivas, tell us more about the trial and what it’s targeted at? Yeah, I mean again, it’s an exploratory study. We wanted to go after a different indication. There’s really no one focused on social anxiety disorder currently with a psychedelic compound. It’s using EMP-01, which we had reported results on in January or so last year. From our Phase 1, we found some very interesting properties of that compound — specifically that it had these antiketogenic effects like MDMA, but it also had psychedelic effects as well. So, a really interesting profile — a blend of these two classes in many ways. We spent time looking for the appropriate indication for that and ultimately made the decision to move forward with social anxiety disorder. There is some limited data for MDMA in social anxiety disorder, particularly in the autism subset, where social anxiety disorder is quite prominent. We are looking at broader social anxiety disorder with this. The trial broadly is a six-week study, with two administrations of EMP-01 — on day one and then at week four — and then a readout at week six. We’re using a regulatory endpoint there, the so-called Liebowitz Social Anxiety Scale (LSAS). Again, very excited to see how this drug performs in this really important patient population, one that has a huge unmet medical need — bigger than depression — and yet has very limited options, at least from the therapeutic options for the treatment. Srinivas, apart from all of those readouts, any other milestones that your investors should be looking out for as 2025 progresses? I think in terms of the things that people will be really focused on, those are the main ones. The readouts are obviously the key right now. Obviously, there are other readouts in the space that we’re all looking at. Compass being an important one. We do remain a shareholder in Compass. They have an interim readout that is also middle of this year. First quarter of next year, I believe, is when the totality of the so-called 005 study will read out. So again, that’s going to be a big one for the space, of course. Quotes have been lightly edited for clarity and style
CMPS’s Market Performance
Compass Pathways Plc ADR (CMPS) has seen a 8.09% rise in stock performance for the week, with a 12.90% gain in the past month and a 12.90% surge in the past quarter. The volatility ratio for the week is 3.40%, and the volatility levels for the past 30 days are at 4.39% for CMPS. . The simple moving average for the past 20 days is 9.83% for CMPS’s stock, with a -3.14% simple moving average for the past 200 days.
Analysts’ Opinion of CMPS
Many brokerage firms have already submitted their reports for CMPS stocks, with Stifel repeating the rating for CMPS by listing it as a “Buy.” The predicted price for CMPS in the upcoming period, according to Stifel is $11 based on the research report published on February 27, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see CMPS reach a price target of $23. The rating they have provided for CMPS stocks is “Outperform” according to the report published on July 23rd, 2024.
Morgan Stanley gave a rating of “Overweight” to CMPS, setting the target price at $30 in the report published on April 01st of the previous year.
CMPS Trading at 25.52% from the 50-Day Moving Average
After a stumble in the market that brought CMPS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.57% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMPS starting from ATAI Life Sciences N.V., who sale 2,660,000 shares at the price of $6.05 back on Sep 26 ’24. After this action, ATAI Life Sciences N.V. now owns 6,905,774 shares of Compass Pathways Plc ADR, valued at $16,093,000 using the latest closing price.
Stock Fundamentals for CMPS
The total capital return value is set at -0.65. Equity return is now at value -60.67, with -43.91 for asset returns.
Based on Compass Pathways Plc ADR (CMPS), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -13.74. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -83.85.
Currently, EBITDA for the company is -178.21 million with net debt to EBITDA at 1.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.18.
Conclusion
In summary, Compass Pathways Plc ADR (CMPS) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
